Abele Stefan Andreas sold $1.8M of PHVS
Abele Stefan Andreas (Chief Technical Ops Officer) sold 46,400 shares of Pharvaris N.V. (PHVS) at an average of $38.17 ($38.14–$39.24, $1.77M total) across 2 trades on 2026-09-15.
How this was made
The 30-second read
Why it matters
The disclosed sale reduces insider ownership, which may be interpreted as a negative cue by the market.
Market read
First‑report insider sale of a C‑level executive; modest materiality for a small‑cap biotech.
What to watch
No 10b5‑1 plan; the timing may be unrelated to company fundamentals.
Background
SEC Form 4 filing discloses insider transactions; PHVS is a biotech listed on Nasdaq.
Ticker impact
Chief Technical Ops Officer sold 46,400 shares for $1.77M, reducing his stake to 39,068 shares.
Modest downside pressure, likely 1‑2% dip over the next few days.
C‑level insider sales are watched closely; the $1.8M sale is material for a small‑cap biotech and could trigger sell‑offs.
Market effects
May raise concerns for other biotech firms with recent insider sales.
Limited to US biotech investors; no broader regional effect.
Minimal global impact.
Counterpoint
The sale could be routine portfolio rebalancing, not a bearish signal.
Key entities
- CompanyPharvaris N.V.
Biotech firm developing therapies for rare diseases.
- IndividualAbele Stefan Andreas
Chief Technical Ops Officer of Pharvaris.
